Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Phase II trial of neoadjuvant (neo) palbociclib (Palbo) plus anastrozole (ana) in endocrine resistant clinical stage 2/3 estrogen receptor positive and HER2 negative (ER+ HER2-) breast cancer (BC).
Northfelt, Donald W. , Forero‐Torres, Andres , Anderson, J. L. , Sanati, Souzan , Cynthia, X. , Bagegni, Nusayba , Gao, Feng , Goetz, Matthew P. , Anderson, Jill, Vij, Kiran R , Ellis, Matthew J.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: TPS592-TPS592

10.1200/jco.2017.35.15_suppl.tps592 Get It

TPS592 Background: Persistent cell proliferation (Ki67 > 10%) on tumor biopsies as early as 2-4 weeks (wks) on neo endocrine therapy (ET) identifies resistant tumors in ~20% patients (pts) with early stage ER+ HER2- BC who are at high risk of relapse. Palbo plus ET significantly improves progression free survival in pts with ET naïve or resistant advanced ER+ HER2- BC, and is being evaluated in the adjuvant setting. However, biomarkers predictive of palbo sensitivity are unknown. Ki67 analysis of serial tumor biopsies in the neo palbo and ana (NeoPalAna) trial demonstrated that 2 wks of palbo plus ana potently inhibited Ki67 and induced complete cell cycle arrest (CCCA, Ki67≤2.7%) in tumors with high Ki67 post 4 wks ana run-in. This study is therefore aimed to prospectively investigate the biological activity of palbo plus ana in ET resistant ER+ HER2- BC. Methods: The primary objective is to assess the rate of CCCA (central Ki67 ≤2.7%) after 2 wks of neo palbo and ana. Secondary objectives include analysis of tumor biopsies to explore response biomarkers. Key inclusions include women with clinical stage 2/3 ER+ HER2- BC, central Ki67 > 10% after ≥2 wks of any neo ET, adequate organ function. Key exclusions include prior CDK 4/6 inhibitor, treatment of BC except ET, concomitant use of strong CYP3A4 inhibitor. Pts receive palbo (125mg PO daily, days 1-21, 28-day cycle), ana (1 mg PO daily) and goserelin (if premenopausal). Pts with C1D15 Ki67 > 10% will discontinue study. If C1D15 Ki67 ≤10%, pt will receive 4 cycles of treatment, and additional 10-12 days of palbo if counts normalized within 3 wks post C4D28. Following surgery, pts are eligible for 2 years of adjuvant palbo. A sample size of 37 (stage 1, n = 12, stage 2 n = 25) by simon optimal two stage phase II design will be employed to assess whether the rate of CCCA is ≤5% vs ≥20% (90% power, alpha 0.1). Stage 2 will proceed if ≥1 had CCCA in stage 1. If ≤3 of 37 had CCCA, this regimen will be considered ineffective. The study is active and has enrolled 4 pts. Clinical trial information: NCT01723774.
Evaluation of tumor and circulating cell free (cf) DNA mutations in women with hormone refractory metastatic breast cancer (MBC) enrolled in a phase I study of Z-endoxifen (MC093C).
Northfelt, Donald W. , Burhow, Sarah A., McGovern, Renee M., Dockter, Travis , Haddad, Tufia C. , Erlichman, Charles , Adjei, Alex A. , Visscher, Daniel W., Kipp, Benjamin R. , Hawse, John R. , Doroshow, James H. , Collins, Jerry M. , Streicher, Howard , Ames, Matthew M. , Liu, Minetta C. , Goetz, Matthew P. , Suman, Vera J. , Reid, Joel M. , Safgren, Stephanie L. , Ingle, James N.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 1043-1043

10.1200/jco.2017.35.15_suppl.1043 Get It

1043 Background: In estrogen receptor (ER) positive MBC, mutations (e.g. ESR1), identified from tumor biopsies or cfDNA, confer resistance. The concordance between mutations observed in tumor and cfDNA and the implications for response to Z-endoxifen, a potent anti-estrogen, are unknown. Methods: We previously conducted a phase I trial of Z-endoxifen in endocrine refractory, ER positive MBC. Seven dose levels were considered ranging from 20 to 160 mg/day followed by expansion cohorts (EC) of 40, 80, and 100 mg/day. Pretreatment blood samples (all pts) and fresh tumor biopsies (EC) were collected prospectively. Tumor and cfDNA were evaluated by targeted NGS. Results: 41 pts (38 evaluable) were enrolled. Prior endocrine therapy included aromatase inhibitors (37/38, 97%), fulvestrant (22/38, 58%) and tamoxifen (26/38, 68%). Substantial endoxifen exposure without DLTs at doses above 80 mg/day led to a halt in dose escalation and opening of the EC. Overall clinical benefit (stable > 6 months [7 pts.] or partial response by RECIST criteria [3 pts.]) rate was 26.3% (95%CI: 13.4-43.1%). cfDNA was obtained from 36 pts and mutations were identified in 13 (36%) including ESR1 [ Y537N or D538G] (5), PIK3CA [ H1047R or E542K] (8), TP53 [ K132R, R248Q, R267Q, or H179Y] (4), AKT ( Q79K) (1), and KRAS ( G12D) (1). In 5 pts with cf ESR1 mutations, 4 had additional cfDNA mutations including PIK3CA (3), and TP53 (1). PFS was shorter in pts with cfDNA mutations relative to those without (median: 61 vs.132 days; log-rank p = 0.021). Discordance was observed between tumor and cfDNA mutations where 3/7 PIK3CA tumor mutations were detected by cfDNA, 1/2 TP53 tumor mutations were detected by cfDNA, and 0/1 AKT tumor mutations were detected by cfDNA. Conversely, 2 pts had cfDNA mutations (either ESR1, TP53 or AKT) undetected in tumor. Conclusions: The absence of cfDNA mutations in patients with endocrine resistant, MBC treated with Z-Endoxifen was associated with significantly longer PFS. Given the discordance between tumor and cfDNA sequence data, future studies must determine which approach maximizes prognosis and prediction of benefit for estrogen-targeted therapy. Clinical trial information: NCT01327781.
Prognostic value of histopathology, stromal tumor infiltrating lymphocytes (sTILs) and adjuvant chemotherapy (AdjCT) in early stage triple negative breast cancer (TNBC).
Leon‐Ferre, Roberto A. , Polley, Mei‐Yin C. , Liu, Heshan , Gilbert, Judith A, Cafourek, Victoria, Akinhanmi, Margaret, Negron, Vivian , Liu, Minetta C. , Visscher, Daniel W., Hillman, David W. , Elkhanany, Ahmed , Boughey, Judy C. , Ingle, James N. , Kalari, Krishna R. , Couch, Fergus J. , Goetz, Matthew P.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 533-533

10.1200/jco.2017.35.15_suppl.533 Get It

533 Background: Current guidelines define TNBC as complete absence of estrogen (ER) and progesterone receptor (PR), without HER2 amplification. However, the prognostic impact of clinical and histopathological factors, sTILs, and AdjCT in TNBC meeting these strict criteria is unknown. Methods: From a cohort of 9985 women who underwent upfront surgery for M0 breast cancer (BC) at Mayo Clinic Rochester from 1985-2012, 1159 pts with ER negative or low (≤10%) BC were identified for central ER/PR/HER2 staining and HER2 FISH (IHC2+ only) to select those with TNBC by modern definitions. Cox proportional hazards models were used to assess the impact of clinicopathological variables on invasive disease-free (IDFS) and overall survival (OS). Results: Tumors from 605 pts (median age 56.3 yrs) met criteria for TNBC (ER < 1%, PR < 1% and HER2 0, 1 or 2+ and FISH negative). 51% were T1, 65% N0, 88% grade 3, and 75% had Ki67 > 15%. Histologically, 39% were anaplastic, 26% invasive ductal, 16% medullary, 8% metaplastic, 6% apocrine and 5% others. Median sTILs was 20% (0-90%). 55% pts received AdjCT [21% anthracycline (A), 19% A + taxane, and 15% other]. Median follow-up for IDFS and OS were 7.4 and 10.6 yrs, respectively. Multivariate analyses demonstrated that higher N stage (p < 0.01), lower sTILs (p = 0.01) and no AdjCT (p < 0.01) were independently associated with worse IDFS and OS. Histology (medullary subtype) was associated with better IDFS in univariate (HR 0.56, 95% CI, 0.35-0.89) but not in multivariate analyses, once sTILs were accounted for. Among systemically untreated pts (n = 182), higher N (p < 0.01) and lower sTILs (p = 0.04) were associated with worse IDFS. For systemically untreated T1N0 pts (n = 111), the 5-yr IDFS was 70% (95% CI, 61-81) [T1a: 83% (95% CI, 63-100), T1b: 68% (95% CI, 52-88) and T1c: 67% (95% CI, 55-83)], compared to 78% (95% CI, 68-84) for T1N0 pts treated with AdjCT. Conclusions: In TNBC pts, N stage, sTILs and receipt of AdjCT were independently prognostic for IDFS and OS. sTILs remained prognostic for IDFS in systemically untreated TNBC. In N0 TNBC, the risk of recurrence or death was substantial in the absence of chemotherapy, even for those with T1 tumors.
Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010.
Molina, Julian R. , Kim, Joo-Hang , Arvis, Catherine Dubos, Ahn, Myung‐Ju , Fidler, Mary J. , Gubens, Matthew A. , Castro, Gilberto de , Shentu, Yue , Im, Ellie, Lubiniecki, Gregory M., Baas, Paul, Garon, Edward B. , Herbst, Roy S. , Kim, Dong‐Wan , Felip, Enriqueta , Perez‐Gracia, José Luis , Han, Ji-Youn , Majem, Margarita , Garrido, Marcelo , Baas, Paul

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 9024-9024

10.1200/jco.2016.34.15_suppl.9024 Get It

Association of vitamin D insufficiency with inferior prognosis in follicular lymphoma.
Tracy, Sean , Ansell, Stephen M. , Nowakowski, Grzegorz S. , Thompson, Carrie A. , Inwards, David J. , Johnston, Patrick B. , Micallef, Ivana N. , Allmer, Cristine, Macon, William R. , Maurer, Matthew J. , Witzig, Thomas E. , Drake, Matthew T. , Weiner, George J. , Slager, Susan L. , Habermann, Thomas M. , Link, Brian K. , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e19067-e19067

10.1200/jco.2016.34.15_suppl.e19067 Get It

MC1463: Avatar-directed chemotherapy in platinum-resistant ovarian cancer.
Long, Beverly, Hou, Xiaonan , Becker, Marc A., VanBlaricom, Jamison L., Bradley, Evans, Hendrickson, Andrea E. Wahner , Oberg, Ann L. , Heinzen, Ethan P. , Camoriano, John , Colón‐Otero, Gerardo , Burton, Jill K., Kalli, Kimberly R., Foster, Nathan R. , Weroha, Saravut J., Maurer, Matthew J. , Haluska, Paul

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: TPS5609-TPS5609

10.1200/jco.2016.34.15_suppl.tps5609 Get It

Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.
Tritchler, David , Starr, Mark D. , Brady, John C. , Hurwitz, Herbert I. , Mannel, Robert S., Tewari, Krishnansu S. , Gray, Heidi J. , Boente, Matthew, Deng, Wei , Burger, Robert A. , Birrer, Michael J. , Secord, Angeles Alvarez , Liu, Yingmiao , Lankes, Heather A. , O’Malley, David M. , Bakkum‐Gamez, Jamie N. , Fujiwara, Keiichi , Deng, Wei, Nixon, Andrew B.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 5521-5521

10.1200/jco.2016.34.15_suppl.5521 Get It

Single-agent LV305 to induce anti-tumor immune and clinical responses in patients with advanced or metastatic sarcoma and other cancers expressing NY-ESO-1.
Somaiah, Neeta , Block, Matthew S. , Tu, Khanh, Hwu, Patrick , Jones, Robin L. , Gnjatic, Sacha , Lu, Hailing , Meulen, Jan ter , Hsu, Frank J., Gnjatic, Sacha , Jones, Robin L , Kim, Joseph W. , Shapiro, Geoffrey I. , Eder, Joseph P. , Pollack, Seth M.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 3093-3093

10.1200/jco.2016.34.15_suppl.3093 Get It

Genome-wide association study (GWAS) of response to androgen deprivation therapy (ADT) and survival in metastatic prostate cancer (PCa).
Pomerantz, Mark M., Wang, Victoria , Lee, Gwo‐Shu Mary , Hahn, Noah M. , Jarrard, David F. , Liu, Glenn , García, Jorge A. , DiPaola, Robert S. , Freedman, Matthew L. , Kantoff, Philip W. , Xie, Wanling , Kohli, Manish , Wang, Elaine, Chen, Yu‐Hui , Carducci, Michael A. , Sweeney, Christopher J.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 1540-1540

10.1200/jco.2016.34.15_suppl.1540 Get It

Eosinophils increase airway sensory nerve density in mice and in human asthma
Drake, Matthew G. , Scott, Gregory D. , Blum, Emily , Lebold, Katie M. , Lee, James J. , Fryer, A.D. , Costello, Richard W. , Jacoby, David B. , Blum, Emily D , Lebold, Katherine M , Fryer, Allison D , Costello, Richard W , Jacoby, David B , Nie, Zhenying , Drake, Matthew G

Mayo Clinic

Science Translational Medicine | September 5, 2018 | Volume: 10 | Issue: 457 | Pages: No page available

10.1126/scitranslmed.aar8477 | PMID 30185653 Get It

Eosinophils increase airway sensory nerve density in humans with asthma and in mice, which promotes airway hyperresponsiveness.